275 related articles for article (PubMed ID: 10361077)
1. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
Binder GM
Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
[TBL] [Abstract][Full Text] [Related]
2. FDA Modernization Act: implications for oncology.
Morris L
Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
[TBL] [Abstract][Full Text] [Related]
3. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
4. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
Kulynych J
Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
[No Abstract] [Full Text] [Related]
5. Regulatory considerations for determining postmarketing study commitments.
Meyer RJ
Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
[TBL] [Abstract][Full Text] [Related]
6. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
7. Investigational new drug applications; clinical holds--FDA. Direct final rule.
Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
[TBL] [Abstract][Full Text] [Related]
8. FDA, off-label use, and informed consent: debunking myths and misconceptions.
Beck JM; Azari ED
Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
[No Abstract] [Full Text] [Related]
9. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
Weeks EA
Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
[No Abstract] [Full Text] [Related]
10. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
11. Current FDA directives for promoting public health.
Hayes AH
Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
[TBL] [Abstract][Full Text] [Related]
12. FDA reform signed into law. Food and Drug Administration.
James JS
AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
[TBL] [Abstract][Full Text] [Related]
13. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
14. FDA perspectives on supplement use by patients on antithrombotic therapy.
Kim MJ
Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
[No Abstract] [Full Text] [Related]
15. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
[TBL] [Abstract][Full Text] [Related]
16. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
[TBL] [Abstract][Full Text] [Related]
17. Off-label drug use.
Dooley AG
Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
[No Abstract] [Full Text] [Related]
18. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
[TBL] [Abstract][Full Text] [Related]
19. New drug and antibiotic regulations--FDA. Proposed rule.
Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
[TBL] [Abstract][Full Text] [Related]
20. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
